The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2.
 
Tina Cascone
Honoraria - American Society of Clinical Oncology; AstraZeneca; Bio Ascend; Brystol-Myers Squibb; Clinical Care Options; IDEOlogy Health; Medical Education Consortium; Medscape; Onclive; PEAK Medicals; Peerview; Physicans' Education Resource; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Merck; oNKo-innate; Pfizer; RAPT Therapeutics; Summit Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bio Ascend; Bristol-Myers Squibb; IDEOlogy Health; Medical Education Consortium; Merck; OncLive/MJH Life Sciences; PEAK Medicals; Peerview
 
Laura Bonanno
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb/Medarex; MSD Oncology; Novartis; Roche/Genentech
Speakers' Bureau - AstraZeneca/MedImmune; Bristol-Myers Squibb/Medarex; Novartis/Ipsen
 
Florian Guisier
Honoraria - Amgen; AstraZeneca; BMS GmbH & Co. KG; Janssen; MSD; Pfizer; Roche; Sanofi; Takeda; Viatris
Consulting or Advisory Role - Amgen; AstraZeneca; BMS GmbH & Co. KG; MSD; Roche; Sanofi
Research Funding - Pfizer (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD; Takeda
 
Maria Amelia Insa Molla
No Relationships to Disclose
 
Moishe Liberman
Stock and Other Ownership Interests - AssistIQ; Ditch Labs; Endocision
Consulting or Advisory Role - Johnson & Johnson
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb/Sanofi (Inst); Cook Medical (Inst); Ethicon/Johnson & Johnson (Inst); Johnson & Johnson/MedTech (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Cryobiopsy Device
 
Olivier Bylicki
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Gilead Sciences; Janssen Oncology; MSD; Takeda
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; MSD; MSD Oncology; MSD Oncology
 
Lorenzo Livi
No Relationships to Disclose
 
Thomas Egenod
No Relationships to Disclose
 
Romain Corre
Honoraria - AstraZeneca/MedImmune; Bristol Myers Squibb; MSD Oncology
Consulting or Advisory Role - Amgen; AstraZeneca; Lilly; MSD Oncology; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Takeda
 
Agata Bielska
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
 
Alula Yohannes
Employment - AstraZeneca/MedImmune
 
Yun He
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
 
Adam Dowson
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
Patents, Royalties, Other Intellectual Property - AstraZeneca/MedImmune
 
Lara McGrath
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
 
Gozde Kar
Employment - AstraZeneca/MedImmune
 
Rakesh Kumar
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
Patents, Royalties, Other Intellectual Property - AstraZeneca/MedImmune
 
Italia Grenga
Employment - AstraZeneca/MedImmune
 
Jonathan Spicer
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb/Medarex; Chemocentryx; Merck; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; Merck; Protalix Biotherapeutics; Regeneron; Xenetic Biosciences
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Medarex (Inst); CLS-Therapeutics (Inst); CLS-Therapeutics (Inst); Merck (Inst); Protalix Biotherapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Medarex; Merck
 
Patrick Forde
Consulting or Advisory Role - Ascendis Pharma; AstraZeneca/MedImmune; BioNTech SE; Bristol-Myers Squibb; CureVac; Daiichi Sankyo/UCB Japan; F-Star Biotechnology; Fosun Pharma; G1 Therapeutics; Genelux; Genelux; Gilead Sciences; ITeos Therapeutics; Janssen; Merck; Novartis; Novocure; Regeneron; Sanofi; Synthekine; Tavotek BioTherapeutics; Teva
Research Funding - AstraZeneca/MedImmune (Inst); BioNTech SE; Bristol-Myers Squibb (Inst); Novartis (Inst); Regeneron